Physician profile
John S Ching
NPI 1770720799
$4,131.46
in general payments reported to CMS, 2019-2025
29 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $448 · 2021: $487 · 2022: $535 · 2023: $487 · 2024: $677 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.03 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.53 | 2019-2024 | Lupron Depot |
| Tolmar, INC. | $424.60 | 2023-2025 | Fensolvi |
| Abbott Laboratories | $337.84 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $322.81 | 2019-2024 | Omnipod |
| Dexcom, INC. | $219.76 | 2019-2023 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $186.21 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $150.82 | 2022-2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $144.47 | 2021-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $133.98 | 2023-2025 | Wegovy, Sogroya |
| Neurocrine Biosciences, INC. | $126.69 | 2025 | |
| Soleno Therapeutics, INC. | $125.76 | 2025 | Vykat Xr |
| Pfizer INC. | $123.50 | 2019-2025 | |
| Beta Bionics, INC. | $122.10 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Zealand Pharma US, INC. | $118.37 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $115.58 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $94.88 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $93.88 | 2023-2024 | Triptodur, Triptodur |
| Lilly USA, LLC | $78.39 | 2019-2020 | |
| Medtronic, INC. | $63.38 | 2023-2025 | Minimed 780g |
| Endo USA, INC. | $55.59 | 2025 | Supprelin |
| Companion Medical, INC. | $43.45 | 2020 | |
| Ferring Pharmaceuticals INC. | $41.52 | 2019-2020 | |
| Sequel Med Tech, LLC | $38.78 | 2025 | Twiist |
| Biomarin Pharmaceutical INC. | $35.58 | 2021-2022 | |
| Mannkind Corporation | $30.93 | 2021 | |
| Medtronic Minimed, INC. | $29.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.73 | 2019 | |
| Lifescan, INC. | $18.17 | 2020 | |
| Vistapharm, INC. | $16.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.